Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation

被引:244
作者
Unitt, Esther
Marshall, Aileen
Gelson, William
Rushbrook, Simon M.
Davies, Susan
Vowler, Sarah L.
Morris, Lesley S.
Coleman, Nicholas
Alexander, Graeme J. M.
机构
[1] Univ Cambridge, Sch Clin Med, Addenbrookes NHS Trust, Dept Med, Cambridge CB2 2QQ, England
[2] Univ Cambridge, Sch Clin Med, Addenbrookes NHS Trust, Dept Histopathol, Cambridge CB2 2QQ, England
[3] Univ Forvie Site, Dept Publ Hlth & Primary Care, Inst Publ Hlth, Ctr Appl Med Stat, Cambridge CB2 2SR, England
[4] MRC, Hutchinson Res Ctr, Canc Cell Unit, Cambridge, England
关键词
hepatocellular carcinoma (HCC); tumour-infiltrating lymphocytes (TILs); Foxp3; regulatory T cells; liver transplantation;
D O I
10.1016/j.jhep.2005.12.027
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Liver transplantation is an effective treatment for highly selected patients with hepatocellular carcinoma (HCC), but tumour recurrence remains an important cause of mortality. There are few data on the relation between the recurrence of HCC and lymphocytic infiltration following liver transplantation. Methods: The tumour CD4(+), CD8(+), CD25(+) and Foxp3(+) lymphocyte infiltrate was assessed by immunohistochemistry in explant tissue of 69 patients who underwent liver transplantation for HCC between 1985 and 2001. The data were analysed according to HCC recurrence and factors known to be associated with outcome. Results: Tumour size (Hazard ratio (95% CI: 1.19 (1.02, 1.39), P = 0.03)), vascular invasion (P = 0.02), lymphocyte infiltration (P = 0.02) and CD4:CD8 ratio (P = 0.001) were identified as significant univariate predictors of tumour recurrence. On multivariate analysis CD4:8 ratio (P = 0.001), vascular invasion (P = 0.01), tumour size (P = 0.06) and reduced lymphocyte infiltration (P = 0.03) were significant independent predictors of recurrence. The presence of Foxp3(+) T-lymphocytes was not predictive of recurrence, but was associated with vascular invasion (FE = 9.02, P = 0.04). Conclusions: The data support the hypothesis that immune responses are important in HCC and that the phenotype of infiltrating lymphocytes is informative regarding prognosis. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:246 / 253
页数:8
相关论文
共 31 条
[1]   CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination [J].
Casares, N ;
Arribillaga, L ;
Sarobe, P ;
Dotor, J ;
de Cerio, ALD ;
Melero, I ;
Prieto, J ;
Borrás-Cuesta, F ;
Lasarte, JJ .
JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :5931-5939
[2]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[3]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[4]   Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells (Reprinted from vol 4, pg 330-336, 2003) [J].
Fontenot, Jason D. ;
Gavin, Marc A. ;
Rudensky, Alexander Y. .
JOURNAL OF IMMUNOLOGY, 2017, 198 (03) :986-992
[5]   Immunologic mechanisms of antitumor activity [J].
Foss, FM .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :5-11
[6]  
Freeman A, 1999, CLIN CANCER RES, V5, P2121
[7]   Regulation of tumour immunity by CD25+ T cells [J].
Gallimore, A ;
Sakaguchi, S .
IMMUNOLOGY, 2002, 107 (01) :5-9
[8]   Induction of immune tolerance toward tumor-associated-antigens enables growth of human hepatoma in mice [J].
Gotsman, I ;
Israeli, D ;
Alper, R ;
Rabbani, E ;
Engelhardt, D ;
Ilan, Y .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (01) :52-57
[9]  
Halpern Allan C., 1997, Seminars in Oncology, V24, P2
[10]  
Hamilton S.R., 2000, WHO CLASSIFICATION T